Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
MYELOMA
Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial
A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma…
Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research at the institution’s Hammersmith…
A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found.
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic, early-stage patients from those…
MYELOMA
clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow — will now be covered…


